Novavax Begins Australian Influenza/COVID-19 Vaccine Trial
American biotech company Novavax announced that it will begin an early-staged trial for a combined influenza/COVID-19 vaccine. The trial will be conducted in Australia and will include 640 adults (between 50 and 70 years of age) and who have either been previously...
UK Study Shows COVID-19 Vaccines Reduce Risk of Long COVID
A UK study has shown that the risk of developing long COVID, as well as severe illness caused by COVID-19, is greatly reduced in a person who is fully vaccinated. Published by the Lancet Infectious Diseases Journal, the study indicates that those who have received...
FDA Asks Eli Lilly, Pfizer, and AbbVie to List JAK Warnings
The US FDA (Food and Drug Administration) has asked Eli Lilly & Co, Pfizer, and AbbVie, to inform consumers about potential risks relating to their high-profile Janus kinase (JAK) inhibitor medications. The FDA has ordered label warnings that list a heightened...
78 Million People With Dementia by 2030, WHO Predicts
Dubbed a global health concern, The WHO (World Health Organization) has projected that the number of people living with dementia will increase to 78 million by the year 2030 and will cost the global economy $1.3 trillion p/a. Currently, there are over 55 million...
EU Vaccinated 70% of Adult Population Against COVID-19
The European Commission announced that 70% of adults in the European Union (EU) are fully vaccinated against COVID-19, meeting the target that was initially set in January 2021, at the start of the vaccine rollout. This milestone marks a success for the EU's...
Eagle Receives USPTO Additional Patent for Bendamustine
Eagle Pharmaceuticals have been granted their U.S. Patent No. 11,103,483 titled, “Formulations of Bendamustine”, by the U.S. Patent and Trademark Office (USPTO). Eagle plans to submit this patent to be included in the FDA’s (Food and Drug Administration’s) Orange Book...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com